The prognostic value of anemia, right-heart catheterization and neurohormones in chronic heart failure

Expert Review of Cardiovascular Therapy

Volumn 4, Issue 1, 2006, Pages 51-57

  Gardner, Roy S ^a   McDonagh, Theresa A ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Anemia; Catheterization; Chronic heart failure; Natriuretic peptides; Neurohormones; Prognosis; Right heart

Indexed keywords

ADRENOMEDULLIN; ALDOSTERONE; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CA 125 ANTIGEN; CATECHOLAMINE DERIVATIVE; CHROMOGRANIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; INTERLEUKIN 6; NEUROHORMONE; NEUROPEPTIDE Y; NORADRENALIN; RENIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANEMIA; CARDIOVASCULAR PARAMETERS; CLINICAL TRIAL; HEART CATHETERIZATION; HEART FAILURE; HEART HEMODYNAMICS; HEART TRANSPLANTATION; HUMAN; INCIDENCE; MEDICAL INSTRUMENTATION; MORTALITY; PREVALENCE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT;

ANEMIA; BIOLOGICAL MARKERS; CHRONIC DISEASE; HEART CATHETERIZATION; HEART FAILURE, CONGESTIVE; HUMANS; NEUROTRANSMITTER AGENTS; PROGNOSIS;

EID: 33646186730     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.4.1.51     Document Type: Review

References (76)

1. Deng MC, De MJ, Smits JM et al. Effect of receiving a heart transplant: analysis of a national cohort entered on to a waiting list, stratified by heart failure severity. Comparative Outcome and Clinical Profiles in Transplantation (COCPIT) Study Group. BMJ321, 540-545 (2000).
2. Stewart S, MacIntyre K, Hole DJ et al. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur. J. Heart Fail. 3, 315-322 (2001).
3. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl J. Med. 344, 1651-1658 (2001).
4. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with a poor outcome. Circulation 107, 223-225 (2003).
5. Anand I, McMurray JJV, Whitmore J et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 110, 149-154 (2004).
6. Izaks GJ, Westendorp RG, Knook DL. The definition of anemia in older persons. JAMA 281, 1714-1717 (1999).
7. Gardner RS, Chong KS, Morton JJ, McDonagh TA. N-terminal brain natriuretic peptide, but not anemia, is a powerful predictor of mortality in advanced heart failure. J. Card. Fail. 11, S47-S53 (2005).
8. Al Ahmad A, Rand W, Manjunath G et al, Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol. 38(4), 955-962 (2001).
9. Plata R, Cornejo A, Arratia C et al. Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. Lancet 359, 663-666 (2002).
10. Horwich TB, Fonarow GC, Hamilton MA et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J. Am. Coll. Cardiol. 39, 1780-1786 (2002).
11. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N. Engl J. Med. 334, 1349-55 (1996).
12. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9-13 (1999).
13. Anand IS, Kuskowski MA, Rector TS et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure. Circulation 112, 1121-1127 (2005).
14. Silverberg DS, Wexler D, Sheps D et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J. Am. Coll. Cardiol. 37, 1775-1780 (2001).
15. Silverberg DS, Wexler D, Blum M et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll. Cardiol. 35, 1737-1744 (2000).
16. Mancini DM, Katz SD, Lang CC et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107, 294-299 (2003).
17. Maggioni AP, Opasich C. Anand I. et al. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J. Card. Fail. 11, 91-98 (2005).
18. Keogh AM, Baron DW, Hickie JB Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation. Am. J. Cardiol. 65, 903-908 (1990).
19. Griffin BP, Shah PK, Ferguson J et al. Incremental prognostic value of exercise hemodynamic variables in chronic congestive heart failure secondary to coronary artery disease or dilated cardiomyopathy. Am. J. Cardiol. 67, 848-853 (1991).
20. Morley D, Brozena S. Assessing risk by hemodynamic profile in patients awaiting cardiac transplantation. Am. J. Cardiol. 73, 379-383 (1994).
21. Komajda M, Jais P, Reeves F et al. Factors predicting mortality in idiopathic dilated cardiomyopathy. Eur. Heart J. 11, 824-831 1990.
22. Saxon LA, Stevenson WG, Middlekauff HR et al. Predicting death from progressive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 72, 62-65 (1993).
23. Gardner RS, Henderson G, McDonagh TA. The prognostic use of right heart catheterization data in patients with advanced heart failure: how relevant are invasive procedures in the risk stratification of advanced heart failure in the era of neurohormones? J. Heart Lung Transplant. 24, 303-309 (2005).
24. Gore JM, Goldberg RJ, Spodick DH et al. A community-wide assessment of the use of pulmonary artery catheters in patients with acute myocardial infarction. Chest 92, 721-727 (1987).
25. Zion MM, Balkin J, Rosenmann D et al. Use of pulmonary artery catheters in patients with acute myocardial infarction: analysis of experience in 5,841 patients in the SPRINT Registry. Chest 98, 1331-1335 (1990).
26. Connors AF, Speroff T, Dawson NV et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA 276, 889-897 (1996).
27. Kirklin JK, Naftel DC, Kirklin JW et al. Pulmonary vascular resistance and the risk of heart transplantation. J. Heart Lung Transplant. 7, 331-336 (1988).
28. Erickson KW, Constanzo-Nordin MR, O'Sullivan EJ et al. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J. Heart Lung Transplant. 9, 526-537 (1990).
29. Hosenpud JD, Bennet LE, Keck BM et al. ISHLT Registry Report: The Registry of the International Society for Heart and Lung Transplantation: Seventeenth Official Report-2000. J. Heart Lung Transplant. 19, 909-931 (2000).
30. Bourge RC, Kirklin JK, Naftel DC et al. Predicting outcome after cardiac transplantations: lessons from the Cardiac Transplant Research Database. Curr. Opinion Cardiol. 12, 136-145 (1997).
31. McCarthy JF, McCarthy PM, Massad MG et al. Risk factors for death after heart transplantation: does a single-centre experience correlate with multicentre registries? Ann. Thoracic. Surgery 65, 1574-1579 (1998).
32. Braunschweig F, Linde C, Eriksson MJ et al. Continuous haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure. Eur. heart J. 23, 59-69 (2002).
33. Adamson PB, Magalski A, Braunschweig F et al. Ongoing right ventricular haemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J. Am. Coll. Cardiol. 41, 565-571 (2003).
34. Jougasaki M, Wei C, McKinley LJ. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 92, 286-289 (1995).
35. Pousset F, Masson F, Chavirovskaia O et al. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur. Heart J. 21, 1009-1014 (2000).
36. Richards AM, Doughty R, Nicholls MG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischaemic left ventricular dysfunction. J. Am. Coll. Cardiol. 37, 1781-1787 (2001).
37. Gardner RS, Chong V, Morton I, McDonagh TA. N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-α in patients referred for consideration of cardiac transplantation. Eur. J. Heart Fail. 7, 253-260 (2005).
38. Tsutamoto T, Wada A, Maeda K et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Eur. Heart J. 20, 1799-1807 (1999).
39. Anand IS, Fisher LD, Chiang YT et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Va1-HeFT). Circulation 107, 1278-1283 (2003).
40. Cowburn PJ, Cleland PJ. Endothelin antagonists for chronic heart failure: do they have a role? Eur. Heart J. 22, 1772-1784 (2001).
41. McMurray JJ, Ray SG, Abdullah I et al. Plasma endothelin in chronic heart failure. Circulation 85, 1374-1379 (1992).
42. Pousset F, Isnard R, Lechat P et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur. Heart J. 18, 254-258 (1997).
43. Pacher R, Stanek B, Hülsmann M et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive haemodynamic evaluation in severe heart failure. J. Am. Coll. Cardiol. 27, 633-641 (1996).
44. Stanek B, Frey B, Hülsmann M et al. Validation of big endothelin plasma levels compared with established neurohormonal markers in patients with severe chronic heart failure. Transplant, Proc. 29, 595-596 (1997).
45. Hülsmann M, Stanek B, Frey B et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis os patients with chronic heart failure. J. Am. Coll. Cardiol. 32, 1695-1700 (1998).
46. Selvais PL, Robert A, Sylvie A et al. Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure. J. Cardiac. Fail. 6 (2000).
47. Cody RJ, Haas GJ, Binkley PF et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85, 504-509 (1992).
48. Rickenbacher PR, Trindade PT, Haywood GA et al. Transplant candidates with severe left ventricular dysfunction managed with medical treatment: characteristic and survival. J. Am. Coll. Cardiol. 27, 1192-1197 (1996).
49. Daggubati S, Parks JR, Overton RM. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc. Res. 36, 246-255 (1997).
50. Gardner RS, Chong KS, Morton JJ, McDonagh TA. N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-α, in patients referred for consideration of cardiac transplantation. Eur. J. Heart Fail. 7(2), 234-241 (2005).
51. Maeda K, Tsutamoto T, Wada A et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am. Heart J. 135, 825-832 (1998).
52. Lerman A, Gibbons RJ, Rodeheffer RJ et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 341, 1105-1109 (1993).
53. Francis GS, Benedict C, Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82, 1724-1729 (1990).
54. Wallen T, Landahl S, Hedner T et al. Atrial natriuretic peptides predict mortality in the elderly. J. Intern. Med. 241, 257-259 (1997).
55. McDonagh TA, Cunningham AD, Morrison CE et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 86, 21-26 (2001).
56. Hulsmann M, Berger R, Sturm B et al. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an out-patient cohort with congestive heart failure. Eur. Heart J. 23, 886-91 (2002).
57. Murdoch DR, Byrne J, Morton JJ, et al. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice. Heart 78, 594-597 (1997).
58. Tsutamoto T, Wada A, Maeda K et al, Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96, 509-516 (1997).
59. McNairy M, Gardetto N, Clopton P et al. Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure. Am. Heart J. 143, 406-411 (2002).
60. Gardner RS, Ozalp F, Murday AJ et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur. Heart J. 24, 1735-1743 (2003).
61. Berger R, Hülsmann M, Strecker K et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105, 2392-2397 (2002).
62. Troughton RW, Frampton CM, Yandle TG et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide concentrations. Lancet 355, 1126-1130 (2000).
63. Wei C, Heublein DM, Perrella MA et al. Natriuretic peptide system in human heart failure. Circulation 88, 1004-1009 (1993).
64. Swedberg K, Eneroth P, Kjekshus J et al., for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 82, 1730-1736 (1990).
65. Ceconi C, Ferrari R, Bachetti T et al. Chromogranin A in heart failure: A novel neurohormonal factor and a predictor for mortality. Eur. Heart J. 23, 967-974 (2002).
66. Nagele H, Bahlo M, Klapdor R et al. CA125 and its relation to cardiac function. Am. Heart J. 137, 1044-1049 (1999).
67. D'Aloia A, Faggiano P, Aurigemma G et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: Relation to clinical severity, hemodynamic and doppler echocardiographic abnormalities and short-term prognosis. J. Am. Coll. Cardiol. 41, 1805-1811 (2003).
68. Levine B, Kalman J, Mayer L et al. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. N. Engl J. Med. 323, 236-241 (1990).
69. McMurray JJ, Abdullah I, Dargie HJ et al. Increased concentrations of tumour necrosis factor in 'cachectic' patients with severe chronic heart failure. Br. Heart J. 66, 356-358 (1991).
70. Tsutamoto T. Wada A, Matsumoto T. Relationship between tumour necrosis factor-α production and oxidative stress in failing hearts of patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 37, 2086-2092 (2001).
71. Ferrari R, Bachetti T, Confortini R et al. Tumour necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92, 1479-1486 (1995).
72. Kell R, Haunstetter A, Dengier TJ. Do cytokines enable risk stratification to be improved in NYHA functional class III patients? Eur. Heart J. 23, 70-78 (2002).
73. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl J. Med. 347(3), 161-167 (2002).
74. Dao Q, Krishnaswamy P. Kazanegra R et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J. Am. Coll. Cardiol. 37, 379-385 (2001).
75. Landray MJ, Lehman R, Arnold I. Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: cross-sectional study. BMJ320, 985-986 (2000).
76. Omland T, Persson A, Ng L et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106, 2913-2918 (2002).